Ipamorelin/Tesamorelin Blend — Research, Dosing & Price Guide

The Ipamorelin/Tesamorelin blend combines Ipamorelin (GHRP) with Tesamorelin (a GHRH analog with FDA-approved status for visceral adiposity reduction). This blend is specifically popular for body composition optimization, particularly visceral fat reduction, leveraging the GHRH+GHRP synergy with Tesamorelin's demonstrated fat-targeting properties.

Like other GHRH+GHRP combinations, this blend exploits synergistic GH release through dual-pathway activation. Tesamorelin is a modified GHRH(1-44) with a trans-3-hexenoic acid group that extends its half-life and receptor binding. It activates pituitary GHRH receptors while Ipamorelin simultaneously activates GHS-R1a, producing amplified GH pulses. Tesamorelin has specific FDA-studied evidence for reducing visceral adipose tissue (VAT) — the metabolically dangerous fat surrounding abdominal organs. This is thought to involve preferential lipolytic signaling in visceral adipocytes through GH-mediated activation of hormone-sensitive lipase and enhanced beta-adrenergic sensitivity in visceral fat.

• Tesamorelin is FDA-approved (Egrifta) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
• The LIPO-046 trial showed tesamorelin reduced visceral adipose tissue by 15–18% over 26 weeks vs. placebo (JAMA, 2010)
• Tesamorelin improved trunk fat and triglycerides without affecting glucose or HbA1c
• Combined GHRH+GHRP protocols consistently show synergistic GH release exceeding either component alone
• IGF-1 levels increase 40–80% with tesamorelin monotherapy; the addition of Ipamorelin may amplify this further

• Standard dose: Tesamorelin 1–2 mg + Ipamorelin 100–200 mcg, once daily subcutaneous injection
• Optimal timing: before bed or upon waking (fasted state)
• FDA-approved tesamorelin dose: 2 mg daily (for HIV-associated lipodystrophy)
• Cycle: 12–26 weeks for visceral fat reduction (per FDA study duration), then reassess
• Inject subcutaneously into abdominal area
• Must be fasted — food blunts GH response
• Some protocols add a second Ipamorelin-only dose at another time point for additional GH pulses

Known Side Effects

• Injection site reactions: erythema, pruritus, swelling (most common with tesamorelin)
• Peripheral edema and fluid retention
• Joint pain (arthralgia) — GH-mediated
• Paresthesia (tingling/numbness in extremities)
• Potential for mild glucose elevation with prolonged use — monitor HbA1c
• Myalgia (muscle pain)

Safety Profile

This blend benefits from tesamorelin's FDA-approved safety data, the most rigorous available for any GHRH analog. The LIPO-046 and extension studies demonstrated safety over 52 weeks. Tesamorelin should not be used in patients with disruption of the hypothalamic-pituitary axis (e.g., from hypophysectomy, pituitary tumor), active malignancy, pregnancy, or known hypersensitivity. IGF-1, glucose, and HbA1c should be monitored every 3–6 months. The addition of Ipamorelin (with its excellent selectivity profile) does not add significant risk. Discontinue if IGF-1 rises above the age-adjusted upper limit of normal.

Weeks 1–4: Improved sleep quality. Subtle improvements in energy and recovery. Mild water retention may occur initially. Weeks 5–12: Progressive visceral fat reduction becomes measurable — waist circumference decreases. Lean mass improves. Skin quality improves. Triglycerides may improve. Weeks 13–26: Continued visceral fat reduction toward maximum benefit. Body composition optimized. IGF-1 elevated 40–80% above baseline. Full anti-aging benefits of optimized GH are realized. Benefits persist for several weeks after discontinuation but gradually return toward baseline.

Prices sourced from peptides.gg marketplace. Prices may vary.